1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legislation

Podcast: Fixing Reimbursement ‘Valley Of Death’ And Repealing The Device Tax Are Top MDMA Priorities, CEO Leahey Says

In an interview about medical device lobbying priorities, the Medical Device Manufacturers Association CEO Mark Leahey talked about efforts to figure out administrative and potentially legislative solutions to gain reimbursement for products sooner after FDA approval. Leahey also argues industry groups are in a better position to permanently repeal the 2.3% medical device excise tax despite previous failures to do so.

Interview

One of the medtech industry's top lobbyists emphasized device tax repeal efforts and speeding the path to reimbursement as two major priorities in the coming year in a recent interview with Medtech Insight.

Mark Leahey, CEO of the Medical Device Manufacturers Association, also talked about Commissioner Scott Gottlieb’s recent decision to step down to spend more time with his family. Leahey thanked the commissioner for his service, particular on issues such as the opioid epidemic and opening up opportunities for device makers to help address the issue. Also, noting that he is a father of young children himself, Leahey commended the commissioner for working to prevent children having access to e-cigarettes despite the issue being a political pitfall

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation

Tariffs Threaten Medtech Innovation And US Position As World Leader, Whitaker Tells Lawmakers

 
• By Brian Bossetta

During his testimony before US senators on the impact of tariffs on critical supply chains, AdvaMed’s Scott Whitaker said the Trump tariffs could jeopardize America’s preeminence in medtech. Other industry experts echoed similar concerns.

Califf Warns Progress May Be In Danger Due To ‘Decimated’ FDA Staff

 
• By Barnaby Pickering

In Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit.

What’s A Diagnostic? WHO Wants To Know

 
• By Elizabeth Orr

The World Health Organization is seeking input from stakeholders to create an official definition of the term ‘diagnostics.’ This initiative follows a 2023 resolution aimed at enhancing global diagnostics capacity; the definition, it is hoped, will help drive the creation of effective health policies. Comments will be accepted until 23 May.